serelaxin

This page shows the latest serelaxin news and features for those working in and with pharma, biotech and healthcare.

New drugs can't keep Novartis sales on the up

year. A decision to drop development of acute heart failure drug serelaxin (RLX030) also pegged back Novartis' profits, forcing the company to take a charge of $200m in the quarter.

Latest news

What future for serelaxin after phase III miss?

Novartis' acute heart failure therapy misses two main endpoints. The failure of Novartis' acute heart failure therapy serelaxin to hit its objectives in a second phase III trial is somewhat embarrassing ... credibility". Novartis had been hoping to build
Novartis boosts cardiovascular pipeline with $1bn Ionis deal

The company launched first-in-class chronic heart failure therapy Entresto (sacubitril and valsartan) in 2015 and is hoping to re-file acute heart failure candidate serelaxin (RLX030) this year.
Novartis says Cosentyx is 'outpacing competitors'

These include RLX030 (serelaxin) for acute heart failure, Fovista (pegpleranib) and RTH258 (brolucizumab) for neovascular age-related macular degeneration (AMD), and novel migraine prevention drug AMG334.
Novartis will file heart failure drug before year-end

Novartis was less successful in its efforts to secure approval of acute heart failure therapy Reasanz (serelaxin), which was rejected by an FDA advisory committee earlier this year because of a
CHMP turns down Avastin for brain cancer

heart failure drug Reasanz (serelaxin).

More from news
Approximately 8 fully matching, plus 8 partially matching documents found.

Latest Intelligence

Heart failure therapy embarks on a new era

Other candidates in mid-stage testing include: natriuretic peptide receptor agonists from Capricor Therapeutics (cenderitide) and Palatin Technologies (PL-3994); Novartis' synthetic human relaxin 2 hormone serelaxin (knocked back by regulators
Interview: Elmar Schnee, Cardiorentis

It's a company with great potential, according to Schnee, who has high hopes for its lead drug candidate ularitide – an investigational product that is in competition with Novartis' serelaxin to ... Because of the serelaxin trial [by Novartis], you saw

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Account Director, Medical Education: Salary TBC

Senior Account Manager, Rare Diseases – Medical Communications, ...: Excellent package

Senior Medical Writer: Salary TBC

Medical Writer: Salary TBC

Account Director, Healthcare Marketing Agency: Salary TBC

Account Director – Healthcare Marketing – Berks: Salary TBC

Engagement Expert, Healthcare Brand Communications, London: Excellent package

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Account Director: Competitive Salary Offered

Senior Account Manager: Competitive Salary Offered

Account Manager / Account Director: Competative

Engagement Specialist, Healthcare Brand Communications, London, ...: circa £50K

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Client Services Director – Medical Education Agency – North West...: Salary TBC

Associate Director: £75, 000-90, 000

Global Business Development Director – Health Education: excellent commission

Editorial Assistant Medical Education Agency: £25, 000 - £26, 000

Home-based Senior Project Manager – Independent Med Ed: Salary TBC

Account Director – Health Policy – Global Agency: Salary TBC

Account Manager / Senior Account Manager: 35, 000-40, 000

Senior Account Director development role to Business Director, H...: Excellent package

Business Director: Competitive Salary Offered

Subscribe to our email news alerts

PMHub

Add my company

AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?: Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement: Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape: Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....